Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts

Houba, PHJ., Boven, E., van der Meulen-Muileman, IH., Leenders, RGG., Scheeren, JW., Pinedo, HM. & Haisma, HJ., 15-Mar-1999, In : Biochemical Pharmacology. 57, 6, p. 673-680 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • PHJ Houba
  • E Boven
  • IH van der Meulen-Muileman
  • RGG Leenders
  • JW Scheeren
  • HM Pinedo
  • HJ Haisma

N-[4-daunorubicin-N-carbonyl (oxymethyl)phenyl] O-beta-glucuronyl carbamate (DNR-GA3) is a glucuronide prodrug of daunorubicin (DNR) which induced a better tumor growth delay than DNR when studied at equitoxic doses in three human ovarian cancer xenografts. These results suggested that the prodrug DNR-GA3 was selectively activated by human p-glucuronidase present in tumor tissue. We determined the pharmacokinetics and distribution of DNR-GA3 in nude mice bearing human ovarian cancer xenografts (OVCAR-3, FMa, A2780, and MRI-H-207). Administration of DNR at 10 mg/kg i.v. (maximum tolerated dose) to OVCAR-3-bearing mice resulted in a peak plasma concentration of the drug of 12.18 mu M (t = I min). DNR-GAS at 100 mg/kg i.v. (approximately 50% of the maximum tolerated dose [MTD]) resulted in a peak plasma concentration of DNR that was 28-fold lower than that after DNR itself; in normal tissues, prodrug injection resulted in 5- to 23-fold lower DNR concentrations. DNR showed a relatively poor uptake into OVCAR-3 tumors with a peak concentration of 2.05 nmol . g(-1) after injection. In the same xenograft, DNR-GA3 resulted in a significantly higher DNR peak concentration of 3.45 nmol . g(-1) (P <0.05). The higher area under the curve of DNR in tumor tissue after DNR-GA3 than after DNR itself would be the result of prodrug activation by beta-glucuronidase. In this respect, a considerably higher beta-glucuronidase activity was found in tumor tissue when compared to plasma. The specific activation of DNR-GA3 by beta-glucuronidase at the tumor site relative to normal organs leads to a more tumor-selective therapy, resulting in greater efficacy without increased toxicity. (C) 1999 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)673-680
Number of pages8
JournalBiochemical Pharmacology
Issue number6
Publication statusPublished - 15-Mar-1999


  • anthracycline prodrugs, daunorubicin, human beta-glucuronidase, human ovarian cancer xenografts, BETA-GLUCURONIDASE

ID: 13020675